Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Uncategorized

Compass Point Downgrades At Home Group to Neutral

Compass Point analyst Jim Chartier downgrades At Home Group (NYSE:HOME) from Buy to Neutral.

byBenzinga Newsdesk

May 10, 2021

1 minute read

Compass Point analyst Jim Chartier downgrades At Home Group (NYSE:HOME) from Buy to Neutral.

FSD Pharma Signs Agreement With Covar Pharmaceuticals To Support Development Of Lucid-PSYCH

By Bill Haddad

Today, 12:39 PM

FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced

CSE:HUGE

Compass Point Upgrades Argo Gr Intl Hldgs to Buy, Announces $61 Price Target

By Benzinga Newsdesk

Today, 12:39 PM

Compass Point analyst Casey Alexander upgrades Argo Gr Intl Hldgs (NYSE:ARGO) from Neutral to Buy and announces $61 price target.

ARGO

Nevro Stock Tanks After Q2 Earnings Miss, Analysts Move To Sidelines

By Vandana Singh

Today, 12:39 PM

Nevro Corp (NYSE:NVRO) posted second-quarter revenue of $102.3 million, +81% Y/Y, missing the consensus of $107.7 million. Total U.S. permanent…

NVRO

Earnings

Doma Holdings: Q2 Earnings Insights

By Benzinga Insights

Today, 12:39 PM

Doma Holdings (NYSE:DOMA) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

DOMA

Compass Point Downgrades At Home Group to Neutral

Related Posts

FSD Pharma Signs Agreement With Covar Pharmaceuticals To Support Development Of Lucid-PSYCH

Compass Point Upgrades Argo Gr Intl Hldgs to Buy, Announces $61 Price Target

Nevro Stock Tanks After Q2 Earnings Miss, Analysts Move To Sidelines

Doma Holdings: Q2 Earnings Insights